175 related articles for article (PubMed ID: 25203263)
1. The impact of pioglitazone on bladder cancer and cardiovascular events.
Lee EJ; Marcy TR
Consult Pharm; 2014 Aug; 29(8):555-8. PubMed ID: 25203263
[TBL] [Abstract][Full Text] [Related]
2. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
Hickson RP; Cole AL; Dusetzina SB
J Manag Care Spec Pharm; 2019 Jan; 25(1):72-79. PubMed ID: 30589625
[TBL] [Abstract][Full Text] [Related]
3. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
Vallarino C; Perez A; Fusco G; Liang H; Bron M; Manne S; Joseph G; Yu S
Clin Drug Investig; 2013 Sep; 33(9):621-31. PubMed ID: 23881565
[TBL] [Abstract][Full Text] [Related]
4. A word of caution regarding pioglitazone.
Usman MS; Rizwan T; Ahmed F
J Pak Med Assoc; 2017 Jan; 67(1):153. PubMed ID: 28065979
[No Abstract] [Full Text] [Related]
5. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone use and risk of bladder cancer: population based cohort study.
Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
[TBL] [Abstract][Full Text] [Related]
10. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
Ripamonti E; Azoulay L; Abrahamowicz M; Platt RW; Suissa S
Diabet Med; 2019 Jan; 36(1):22-35. PubMed ID: 30378165
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
Ryder RE
Diabet Med; 2015 Mar; 32(3):305-13. PubMed ID: 25472014
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
17. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
18. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Erdmann E; Harding S; Lam H; Perez A
Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
[TBL] [Abstract][Full Text] [Related]
19. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]